Table 1. Characteristics of the total study population.
| N=196 | |
|---|---|
| Sex | |
| Male | 88 (45%) |
| Female | 108 (55%) |
| Age (years) | |
| Median (range) | 64 (18–89) |
| Primary tumour site | |
| Appendix | 5 (3%) |
| Small bowel | 86 (44%) |
| Large bowel | 22 (11%) |
| Lung | 21 (10%) |
| Pancreas | 17 (9%) |
| Other | 4 (2%) |
| Unknown | 41 (21%) |
| Metastases | |
| No | 57 (29%) |
| Yes | 139 (71%) |
| Carcinoid syndrome | |
| No | 66 (34%) |
| Yes | 130 (66%) |
| GFR | |
| Normal | 171 (87%) |
| Decreased | 25 (13%) |
| Number of CgA measurements | |
| Median (range) | 6 (2–27) |
| CgA level | |
| Normal | 55 (28%) |
| Elevated (attributed to NET) | 122 (62%) |
| Elevated (not attributed to NET) | 19 (10%) |
| PPI use | |
| No | 145 (74%) |
| Yes | 51 (26%) |
Abbreviations: CgA=chromogranin A; GFR=glomerular filtration rate; NET=neuroendocrine tumour; PPI=proton pump inhibitor.